Appili Therapeutics Inc - Asset Resilience Ratio

Latest as of March 2022: 0.00%

Appili Therapeutics Inc (APLI) has an Asset Resilience Ratio of 0.00% as of March 2022. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check APLI PP&E to net assets ratio to assess the company's strategic physical and investment asset allocation.

Liquid Assets

CA$0.00

≈ $0.00 USD Cash + Short-term Investments

Total Assets

CA$8.28 Million

≈ $5.99 Million USD All company assets

Resilience Assessment

Low

Financial Resilience Level

Asset Resilience Ratio Trend (2017–2022)

This chart shows how Appili Therapeutics Inc's Asset Resilience Ratio has changed over time. See APLI equity financing ratio to measure how much of total assets are equity-financed.

Liquid Assets Composition Over Time

This chart breaks down Appili Therapeutics Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market value of Appili Therapeutics Inc.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	CA$0.00	0%
Short-term Investments	CA$0.00	0%
Total Liquid Assets	CA$0.00	0.00%

Asset Resilience Insights

Limited Liquidity: Appili Therapeutics Inc maintains only 0.00% of assets in liquid form.
This low level may indicate efficient asset utilization but could pose risks during economic downturns.
The company maintains a balanced mix of cash and short-term investments.

Appili Therapeutics Inc Industry Peers by Asset Resilience Ratio

Compare Appili Therapeutics Inc's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Argen-X F:1AE	Biotechnology	10.93%
CSL Ltd AU:CSL	Biotechnology	0.41%
Tango Therapeutics Inc NASDAQ:TNGX	Biotechnology	57.90%
HLB Co. Ltd KQ:028300	Biotechnology	0.72%
SOLENO THERAPEUT. DL-001 F:6XC	Biotechnology	41.74%
MBX Biosciences, Inc. Common Stock NASDAQ:MBX	Biotechnology	87.20%
Tourmaline Bio Inc. NASDAQ:TRML	Biotechnology	77.17%
PharmaResources (Shanghai) Co. Ltd. A SHE:301230	Biotechnology	16.35%

Annual Asset Resilience Ratio for Appili Therapeutics Inc (2017–2022)

The table below shows the annual Asset Resilience Ratio data for Appili Therapeutics Inc.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2022-03-31	0.00%	CA$0.00 ≈ $0.00	CA$8.28 Million ≈ $5.99 Million	--
2021-03-31	27.63%	CA$5.06 Million ≈ $3.66 Million	CA$18.32 Million ≈ $13.25 Million	+27.36pp
2020-03-31	0.27%	CA$30.54K ≈ $22.09K	CA$11.17 Million ≈ $8.08 Million	-0.17pp
2019-03-31	0.45%	CA$30.48K ≈ $22.05K	CA$6.84 Million ≈ $4.94 Million	+0.02pp
2018-03-31	0.42%	CA$30.32K ≈ $21.93K	CA$7.19 Million ≈ $5.20 Million	-0.36pp
2017-03-31	0.78%	CA$20.14K ≈ $14.57K	CA$2.57 Million ≈ $1.86 Million	--

pp = percentage points

About Appili Therapeutics Inc

TO:APLI Canada Biotechnology

Market Cap

$1.39 Million

CA$1.93 Million CAD

Market Cap Rank

#30288 Global

#1547 in Canada

Share Price

CA$0.02

Change (1 day)

+0.00%

52-Week Range

CA$0.01 - CA$0.04

All Time High

CA$1.87